Conversely, twice as many TTP-low breast cancers are HER2-positive (HER2+) compared to the TTP-high cohort, indicating that such patients might have an improved response to trastuzumab (Herceptin), which targets HER2 [28]. This evidence concerns the gene ERBB2 and breast carcinoma.